(b) End-stage liver disease

Characteristicsa	Total		Screened positive		Screened negative		Verified ESLD		Randomly selected subcohortb
	n = 41 463		n = 2024		n = 39 439		n = 645		n = 2422
Demographics
Median age at enrollment (years, IQR)	39	(33, 46)	41	(36, 48)	39	(33, 45)	43	(36, 50)	39	(33, 45)
Male sex (n, %)	33 024	80%	1596	79%	31 428	80%	548	85%	1880	78%
Race and ethnicity (n, %)
Non-Hispanic black	14 107	34%	764	38%	13 343	34%	180	28%	992	41%
Non-Hispanic white	17 216	42%	901	45%	16 315	41%	323	50%	985	41%
Hispanic	4803	12%	207	10%	4596	12%	75	12%	186	8%
Other/unknown	5337	13%	152	8%	5185	13%	66	10%	277	11%
HIVtransmissionrisk (n, %)c
Men who have sex with men	20 006	48%	772	38%	19 234	49%	262	41%	1,087	45%
Injection drug use	6087	15%	581	29%	5506	14%	193	30%	411	17%
Heterosexual contact	10 576	26%	503	25%	10 073	26%	123	19%	716	30%
Other/unknown	4794	12%	168	8%	4626	12%	66	10%	226	9%
Hepatitis B/C coinfection
Hepatitis C infection (n, %)	8392	20%	1035	51%	7357	19%	375	58%	588	24%
Hepatitis B infection (n, %)	3938	9%	345	17%	3593	9%	151	23%	234	10%

^aCharacteristics were measured at enrollment into the cohort with the exception of hepatitis C infection; evidence of hepatitis C infection at enrollment or under observation classified an individual as having infection. Hepatitis B infection was defined by a positive hepatitis B surface antigen or detectable hepatitis B DNA result. Hepatitis C infection was defined as a positive hepatitis C antibody or detectable hepatitis C RNA or genotype result.

^bThe subcohort is the group of randomly selected individuals from contributing cohorts, all of whom underwent comprehensive medical record review.

^cMen who have sex with men who also reported injection drug use were classified as injection drug use risk.